Toggle menu

EMBOL1

Start date:
June 2019
End date:
July 2020
Co-ordinated by:
LUMIRADx
Main trial site:
Manchester Royal Infirmary

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). It is the third most frequent cardiovascular disease with an overall annual incidence of
100–200 per 100 000 inhabitants. VTE may be lethal in the acute phase or lead to chronic disease and disability, but it is also often preventable. This study aims to assess the precision and accuracy of the LumiraDx point of Care (POC) D Dimer test when used in patients presenting with symptoms of VTE which can deliver a quantitative result in under 10 minutes from a finger stick blood sample. Current tests require venous blood samples or are laboratory tests that take 30-60+ minutes to return a result to the attending clinician.

Primary Objective: To determine the performance of the LumiraDx POC D Dimer assay when compared to the VIDAS D-Dimer Exclusion reference method in patients with suspected VTE.

Secondary objectives:

  1. Performance evaluation of the haematocrit measurement by the LumiraDx POC D Dimer test with Hemocue Hb 201 system.
  2. Clinical performance of the LumiraDx POC D Dimer assay when used as an aid in the exclusion of DVT and PE.

Sample: Patients presenting to the Emergency department with symptoms of deep vein thrombosis or pulmonary embolism.

Trial design: Prospective observational (cohort) Performance evaluation study

Target – 100 (TBC)

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Polly Black

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Sian Dalgleish

Senior Research Nurse

Emma Nugent

Research Administrator

Fraser Craig

Clinical Trial Assistant

More EMERGE Trials

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE- CTCA

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)